Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Plans to Partner its CD-47 Immunotherapy in $2 Billion Deal

publication date: Apr 29, 2020

According to Bloomberg, I-Mab BioPharma of Shanghai is shopping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration. I-Mab believes TJC4 is a potential global best-in-class CD47 because it binds to a unique epitope on CD47 that leads to only minimal red blood cell binding. In pre-clinical studies, it did not cause anemia, thrombocytopenia or the so-called "antigen sink effect." Like other CD47 candidates, TJC4 works by preventing microphages from being neutralized by the patient's immune system. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.